|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cummins DL, Cummins JM, Pantle H,
Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant
melanoma. Mayo Clin Proc. 81:500–507. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chi Z, Li S, Sheng X, Si L, Cui C, Han M
and Guo J: Clinical presentation, histology, and prognoses of
malignant melanoma in ethnic Chinese: A study of 522 consecutive
cases. BMC Cancer. 11:852011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Callahan MK, Postow MA and Wolchok JD:
Immunomodulatory therapy for melanoma: Ipilimumab and beyond. Clin
Dermatol. 31:191–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poust JC, Woolery JE and Green MR:
Management of toxicities associated with high-dose interleukin-2
and biochemotherapy. Anticancer Drugs. 24:1–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lopez-Bergami P, Fitchman B and Ronai Z:
Understanding signaling cascades in melanoma. Photochem Photobiol.
84:289–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kortylewski M, Jove R and Yu H: Targeting
STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev.
24:315–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie TX, Huang FJ, Aldape KD, Kang SH, Liu
M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3
in human melanoma promotes brain metastasis. Cancer Res.
66:3188–3196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Messina JL, Yu H, Riker AI, Munster PN,
Jove RL and Daud AI: Activated stat-3 in melanoma. Cancer control.
15:196–201. 2008.PubMed/NCBI
|
|
11
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu L, Nam S, Tian Y, Yang F, Wu J, Wang
Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L, et al:
6-Bromoindirubin-3-oxime inhibits JAK/STAT3 signaling and induces
apoptosis of human melanoma cells. Cancer Res. 71:3972–3979. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu L, Kritsanida M, Magiatis P, Gaboriaud
N, Wang Y, Wu J, Buettner R, Yang F, Nam S, Skaltsounis L, et al: A
novel 7-bromoindirubin with potent anticancer activity suppresses
survival of human melanoma cells associated with inhibition of
STAT3 and Akt signaling. Cancer Biol Ther. 13:1255–1261. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kamran MZ and Gude RP: Pentoxifylline
inhibits melanoma tumor growth and angiogenesis by targeting STAT3
signaling pathway. Biomed Pharmacother. 67:399–405. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Martínez ME, Marshall JR and Giovannucci
E: Diet and cancer prevention: The roles of observation and
experimentation. Nat Rev Cancer. 8:694–703. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tong LX and Young LC: Nutrition: The
future of melanoma prevention? J Am Acad Dermatol. 71:151–160.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fortes C, Forastiere F, Farchi S, Mallone
S, Trequattrinni T, Anatra F, Schmid G and Perucci CA: The
protective effect of the Mediterranean diet on lung cancer. Nutr
Cancer. 46:30–37. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bosetti C, Negri E, Franceschi S, Talamini
R, Montella M, Conti E, Lagiou P, Parazzini F and La Vecchia C:
Olive oil, seed oils and other added fats in relation to ovarian
cancer (Italy). Cancer Causes Control. 13:465–470. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Monti MC, Margarucci L, Tosco A, Riccio R
and Casapullo A: New insights on the interaction mechanism between
tau protein and oleocanthal, an extra-virgin olive-oil bioactive
component. Food Funct. 2:423–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Monti MC, Margarucci L, Riccio R and
Casapullo A: Modulation of tau protein fibrillization by
oleocanthal. J Nat Prod. 75:1584–1588. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lucas L, Russell A and Keast R: Molecular
mechanisms of inflammation. Anti-inflammatory benefits of virgin
olive oil and the phenolic compound oleocanthal. Curr Pharm Des.
17:754–768. 2011.
|
|
22
|
Cicerale S, Breslin PA, Beauchamp GK and
Keast RS: Sensory characterization of the irritant properties of
oleocanthal, a natural anti-inflammatory agent in extra virgin
olive oils. Chem Senses. 34:333–339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Romero C, Medina E, Vargas J, Brenes M and
De Castro A: In vitro activity of olive oil polyphenols against
Helicobacter pylori. J Agric Food Chem. 55:680–686. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Busnena BA, Foudah AI, Melancon T and El
Sayed KA: Olive secoiridoids and semisynthetic bioisostere
analogues for the control of metastatic breast cancer. Bioorg Med
Chem. 21:2117–2127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akl MR, Ayoub NM, Mohyeldin MM, Busnena
BA, Foudah AI, Liu YY and Sayed KA: Olive phenolics as c-Met
inhibitors: (−)-Oleocanthal attenuates cell proliferation,
invasiveness, and tumor growth in breast cancer models. PLoS One.
9:e976222014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elnagar AY, Sylvester PW and El Sayed KA:
(−)-Oleocanthal as a c-Met inhibitor for the control of metastatic
breast and prostate cancers. Planta Med. 77:1013–1019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scotece M, Gómez R, Conde J, Lopez V,
Gómez-Reino JJ, Lago F, Smith AB III and Gualillo O: Oleocanthal
inhibits proliferation and MIP-1α expression in human multiple
myeloma cells. Curr Med Chem. 20:2467–2475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pei T, Meng Q, Han J, Li HS, Song R, Sun
B, Pan S, Liang D and Liu L: (−)-Oleocanthal inhibits growth and
metastasis by blocking activation of STAT3 in human hepatocellular
carcinoma. Oncotarget. Jun 2–2016.(Epub ahead of print).
|
|
29
|
Smith AB III, Han Q, Breslin PA and
Beauchamp GK: Synthesis and assignment of absolute configuration of
(−)-oleocanthal: A potent, naturally occurring non-steroidal
anti-inflammatory and anti-oxidant agent derived from extra virgin
olive oils. Org Lett. 7:5075–5078. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song R, Song H, Liang Y, Yin D, Zhang H,
Zheng T, Wang J, Lu Z, Song X, Pei T, et al: Reciprocal activation
between ATPase inhibitory factor 1 and NF-κB drives hepatocellular
carcinoma angiogenesis and metastasis. Hepatology. 60:1659–1673.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Al Zaid Siddiquee K and Turkson J: STAT3
as a target for inducing apoptosis in solid and hematological
tumors. Cell Res. 18:254–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fan TP, Yeh JC, Leung KW, Yue PY and Wong
RN: Angiogenesis: From plants to blood vessels. Trends Pharmacol
Sci. 27:297–309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tournaire R, Simon MP, le Noble F,
Eichmann A, England P and Pouysségur J: A short synthetic peptide
inhibits signal transduction, migration and angiogenesis mediated
by Tie2 receptor. EMBO Rep. 5:262–267. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hartman ML and Czyz M: Anti-apoptotic
proteins on guard of melanoma cell survival. Cancer Lett.
331:24–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhuang L, Lee CS, Scolyer RA, McCarthy SW,
Zhang XD, Thompson JF and Hersey P: Mcl-1, Bcl-XL and Stat3
expression are associated with progression of melanoma whereas
Bcl-2, AP-2 and MITF levels decrease during progression of
melanoma. Mod Pathol. 20:416–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Niu G, Bowman T, Huang M, Shivers S,
Reintgen D, Daud A, Chang A, Kraker A, Jove R and Yu H: Roles of
activated Src and Stat3 signaling in melanoma tumor cell growth.
Oncogene. 21:7001–7010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ascierto PA, Leonardi E, Ottaiano A,
Napolitano M, Scala S and Castello G: Prognostic value of serum
VEGF in melanoma patients: A pilot study. Anticancer Res.
24:4255–4258. 2004.PubMed/NCBI
|
|
39
|
Rotte A, Martinka M and Li G: MMP2
expression is a prognostic marker for primary melanoma patients.
Cell Oncol (Dordr). 35:207–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nikkola J, Vihinen P, Vuoristo MS,
Kellokumpu-Lehtinen P, Kähäri VM and Pyrhönen S: High serum levels
of matrix metalloproteinase-9 and matrix metalloproteinase-1 are
associated with rapid progression in patients with metastatic
melanoma. Clin Cancer Res. 11:5158–5166. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F,
Sawaya R and Huang S: Stat3 activation regulates the expression of
matrix metalloproteinase-2 and tumor invasion and metastasis.
Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
|
